STOCK TITAN

[S-8] Aon plc Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. (DMAC) filed a Form 4 indicating that 10% owner Richard Jacinto II bought 400,000 voting common shares on 07/23/2025 at $3.50 per share. The filing was submitted on 07/25/2025.

The transaction, coded “P,” was executed indirectly through his NFS/FMTC Roth IRA. Following the purchase, the account holds 4,958,823 DMAC shares. Table II shows no derivative securities activity.

The report was filed by a single reporting person who remains subject to Section 16 obligations and lists indirect ownership of the acquired shares.

DiaMedica Therapeutics Inc. (DMAC) ha presentato un Modulo 4 che indica che Richard Jacinto II, proprietario del 10%, ha acquistato 400.000 azioni ordinarie con diritto di voto il 23/07/2025 al prezzo di 3,50 dollari per azione. La dichiarazione è stata inviata il 25/07/2025.

L'operazione, codificata come “P,” è stata effettuata indirettamente tramite il suo NFS/FMTC Roth IRA. Dopo l'acquisto, il conto detiene 4.958.823 azioni DMAC. La Tabella II non mostra attività relative a titoli derivati.

Il rapporto è stato presentato da una singola persona soggetta agli obblighi della Sezione 16 e indica la proprietà indiretta delle azioni acquisite.

DiaMedica Therapeutics Inc. (DMAC) presentó un Formulario 4 indicando que Richard Jacinto II, propietario del 10%, compró 400,000 acciones comunes con derecho a voto el 23/07/2025 a $3.50 por acción. La presentación se realizó el 25/07/2025.

La transacción, codificada como “P,” se ejecutó de forma indirecta a través de su NFS/FMTC Roth IRA. Tras la compra, la cuenta posee 4,958,823 acciones de DMAC. La Tabla II no muestra actividad de valores derivados.

El informe fue presentado por una sola persona informante que sigue sujeta a las obligaciones de la Sección 16 y detalla la propiedad indirecta de las acciones adquiridas.

DiaMedica Therapeutics Inc. (DMAC)는 10% 지분 보유자인 Richard Jacinto II가 2025년 7월 23일 주당 3.50달러에 400,000주 의결권 보통주를 매수했다는 내용의 Form 4를 제출했습니다. 해당 신고는 2025년 7월 25일에 제출되었습니다.

거래는 “P” 코드로 표시되었으며 그의 NFS/FMTC Roth IRA를 통해 간접적으로 실행되었습니다. 매수 후 해당 계좌는 4,958,823주의 DMAC 주식을 보유하고 있습니다. 표 II에서는 파생 증권 활동이 없습니다.

이 보고서는 단일 보고자가 제출했으며 섹션 16 의무를 계속 준수하고 있으며 취득한 주식에 대한 간접 소유권을 명시하고 있습니다.

DiaMedica Therapeutics Inc. (DMAC) a déposé un formulaire 4 indiquant que Richard Jacinto II, propriétaire de 10%, a acheté 400 000 actions ordinaires avec droit de vote le 23/07/2025 au prix de 3,50 $ par action. Le dépôt a été effectué le 25/07/2025.

La transaction, codée « P », a été réalisée indirectement via son NFS/FMTC Roth IRA. Après cet achat, le compte détient 4 958 823 actions DMAC. Le tableau II ne montre aucune activité liée à des titres dérivés.

Le rapport a été déposé par une seule personne déclarant, toujours soumise aux obligations de la Section 16, et mentionne la propriété indirecte des actions acquises.

DiaMedica Therapeutics Inc. (DMAC) reichte ein Formular 4 ein, das angibt, dass der 10% Eigentümer Richard Jacinto II am 23.07.2025 400.000 stimmberechtigte Stammaktien zu einem Preis von 3,50 USD pro Aktie gekauft hat. Die Einreichung erfolgte am 25.07.2025.

Die Transaktion, codiert mit „P“, wurde indirekt über sein NFS/FMTC Roth IRA ausgeführt. Nach dem Kauf hält das Konto 4.958.823 DMAC-Aktien. Tabelle II zeigt keine Aktivitäten mit derivativen Wertpapieren.

Der Bericht wurde von einer einzelnen meldenden Person eingereicht, die weiterhin den Verpflichtungen nach Abschnitt 16 unterliegt und den indirekten Besitz der erworbenen Aktien angibt.

Positive
  • 400,000 shares purchased on 07/23/2025 at $3.50, totaling approximately $1.4 M.
  • Indirect holdings increased to 4,958,823 shares in the Roth IRA.
Negative
  • None.

Insights

TL;DR: 10% owner’s $1.4 M buy adds 400 K DMAC shares, lifting indirect stake to nearly 5 M—generally viewed as constructive insider activity.

The Form 4 discloses a sizeable open-market purchase (code “P”) at $3.50 per share, totaling roughly $1.4 million. Such accumulation by a 10% owner increases his indirect holdings to 4,958,823 shares, reinforcing alignment with shareholders. No sales or derivative transactions were reported, simplifying the ownership picture. While Form 4s do not provide strategic rationale, the scale of buying, relative to existing stake, is material and tends to be interpreted positively by the market.

DiaMedica Therapeutics Inc. (DMAC) ha presentato un Modulo 4 che indica che Richard Jacinto II, proprietario del 10%, ha acquistato 400.000 azioni ordinarie con diritto di voto il 23/07/2025 al prezzo di 3,50 dollari per azione. La dichiarazione è stata inviata il 25/07/2025.

L'operazione, codificata come “P,” è stata effettuata indirettamente tramite il suo NFS/FMTC Roth IRA. Dopo l'acquisto, il conto detiene 4.958.823 azioni DMAC. La Tabella II non mostra attività relative a titoli derivati.

Il rapporto è stato presentato da una singola persona soggetta agli obblighi della Sezione 16 e indica la proprietà indiretta delle azioni acquisite.

DiaMedica Therapeutics Inc. (DMAC) presentó un Formulario 4 indicando que Richard Jacinto II, propietario del 10%, compró 400,000 acciones comunes con derecho a voto el 23/07/2025 a $3.50 por acción. La presentación se realizó el 25/07/2025.

La transacción, codificada como “P,” se ejecutó de forma indirecta a través de su NFS/FMTC Roth IRA. Tras la compra, la cuenta posee 4,958,823 acciones de DMAC. La Tabla II no muestra actividad de valores derivados.

El informe fue presentado por una sola persona informante que sigue sujeta a las obligaciones de la Sección 16 y detalla la propiedad indirecta de las acciones adquiridas.

DiaMedica Therapeutics Inc. (DMAC)는 10% 지분 보유자인 Richard Jacinto II가 2025년 7월 23일 주당 3.50달러에 400,000주 의결권 보통주를 매수했다는 내용의 Form 4를 제출했습니다. 해당 신고는 2025년 7월 25일에 제출되었습니다.

거래는 “P” 코드로 표시되었으며 그의 NFS/FMTC Roth IRA를 통해 간접적으로 실행되었습니다. 매수 후 해당 계좌는 4,958,823주의 DMAC 주식을 보유하고 있습니다. 표 II에서는 파생 증권 활동이 없습니다.

이 보고서는 단일 보고자가 제출했으며 섹션 16 의무를 계속 준수하고 있으며 취득한 주식에 대한 간접 소유권을 명시하고 있습니다.

DiaMedica Therapeutics Inc. (DMAC) a déposé un formulaire 4 indiquant que Richard Jacinto II, propriétaire de 10%, a acheté 400 000 actions ordinaires avec droit de vote le 23/07/2025 au prix de 3,50 $ par action. Le dépôt a été effectué le 25/07/2025.

La transaction, codée « P », a été réalisée indirectement via son NFS/FMTC Roth IRA. Après cet achat, le compte détient 4 958 823 actions DMAC. Le tableau II ne montre aucune activité liée à des titres dérivés.

Le rapport a été déposé par une seule personne déclarant, toujours soumise aux obligations de la Section 16, et mentionne la propriété indirecte des actions acquises.

DiaMedica Therapeutics Inc. (DMAC) reichte ein Formular 4 ein, das angibt, dass der 10% Eigentümer Richard Jacinto II am 23.07.2025 400.000 stimmberechtigte Stammaktien zu einem Preis von 3,50 USD pro Aktie gekauft hat. Die Einreichung erfolgte am 25.07.2025.

Die Transaktion, codiert mit „P“, wurde indirekt über sein NFS/FMTC Roth IRA ausgeführt. Nach dem Kauf hält das Konto 4.958.823 DMAC-Aktien. Tabelle II zeigt keine Aktivitäten mit derivativen Wertpapieren.

Der Bericht wurde von einer einzelnen meldenden Person eingereicht, die weiterhin den Verpflichtungen nach Abschnitt 16 unterliegt und den indirekten Besitz der erworbenen Aktien angibt.

As filed with the Securities and Exchange Commission on July 25, 2025

No. 333-   

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

AON PLC

(Exact name of registrant as specified in its charter)

 

 

 

Ireland   98-1539969

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

15 George’s Quay, Dublin 2, Ireland   D02 VR98
(Address of Principal Executive Offices)   (Zip Code)

Aon plc 2011 Incentive Plan

(Full Title of the Plan)

Darren Zeidel

Executive Vice President, General Counsel and Company Secretary

Aon plc

200 East Randolph Street

Chicago, Illinois 60601

+1 (312) 381-1000

(Name, address and telephone number, including area code, of agent for service)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer  

   Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 
 


REGISTRATION OF ADDITIONAL SHARES

PURSUANT TO GENERAL INSTRUCTION E

Explanatory Note

This Registration Statement on Form S-8 (this “Registration Statement”) is filed by Aon plc (the “Company”) to register an additional 3,800,000 Class A Ordinary Shares, nominal value $0.01 per share, that may be offered and sold pursuant to the Aon plc 2011 Incentive Plan, as amended and restated (the “Plan”). The Company’s shareholders approved the Plan, which provides for the issuance of an additional 3,800,000 shares thereunder, at the Company’s annual general meeting of shareholders on June 27, 2025.

The additional shares registered pursuant to this Registration Statement are of the same class as the other securities subject to the Plan for which the Company previously filed Registration Statements on Form S-8 with the Securities and Exchange Commission (the “Commission”) on June 9, 2011 (Registration No. 333-174788), as amended by the Post-Effective Amendments Nos. 1 and 2 thereto filed with the Commission on April 2, 2012 and April 2, 2020, respectively, October 31, 2014 (Registration No. 333-199759), as amended by the Post-Effective Amendment No. 1 thereto filed with the Commission on April 2, 2020, November 27, 2019 (Registration No. 333-235296), as amended by the Post-Effective Amendment No. 1 thereto filed with the Commission on April 2, 2020, and November 20, 2023 (Registration No. 333-275661). The contents of these registration statements are hereby incorporated herein by reference to the extent not otherwise amended or superseded by the contents hereof pursuant to General Instruction E.

Part II

Information Required in the Registration Statement

Item 8. Exhibits.

 

Exhibit

Number

  

Description of Exhibit

  4.1    Memorandum and Articles of Association of Aon plc (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K of the Company filed with the Commission on June 4, 2021).
  4.2    Aon plc 2011 Incentive Plan, as Amended and Restated (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Commission on July 3, 2025).
  5.1*    Opinion of Matheson LLP.
 23.1*    Consent of Matheson LLP (included in Exhibit 5.1).
 23.2*    Consent of Ernst & Young LLP.
 24.1    Power of Attorney (included on the signature pages to this Registration Statement).
107.1*    Filing Fee Table.

 

*   Filed herewith.


Signatures

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Dublin, Ireland, on July 25, 2025.

 

AON PLC
By:   /s/ Edmund Reese
  Name: Edmund Reese
  Title: Executive Vice President and Chief Financial Officer

Power of Attorney

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Edmund Reese, Darren Zeidel, Michael Neller and Colby Alexis, or any of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated and on the dates indicated.

 

Signature

  

Title

 

Date

/s/ Gregory C. Case

Gregory C. Case

  

Chief Executive Officer and Director

(Principal Executive Officer)

  July 25, 2025

/s/ Lester B. Knight

Lester B. Knight

   Non-Executive Chairman and Director   July 25, 2025

/s/ Jose Antonio Álvarez

Jose Antonio Álvarez

   Director   July 25, 2025

/s/ Jin-Yong Cai

Jin-Yong Cai

   Director   July 25, 2025

/s/ Jeffrey C. Campbell

Jeffrey C. Campbell

   Director   July 25, 2025

/s/ Cheryl A. Francis

Cheryl A. Francis

   Director   July 25, 2025


/s/ Adriana Karaboutis

Adriana Karaboutis

   Director   July 25, 2025

/s/ Richard C. Notebaert

Richard C. Notebaert

   Director   July 25, 2025

/s/ Gloria Santona

Gloria Santona

   Director   July 25, 2025

/s/ Sarah Smith

Sarah Smith

   Director   July 25, 2025

/s/ Byron Spruell

Byron Spruell

   Director   July 25, 2025

/s/ James Stavridis

James Stavridis

   Director   July 25, 2025

/s/ Edmund Reese

Edmund Reese

  

Chief Financial Officer

(Principal Financial Officer)

  July 25, 2025

/s/ Michael Neller

Michael Neller

  

Global Controller

(Principal Accounting Officer)

  July 25, 2025

FAQ

How many DMAC shares did Richard Jacinto II buy on 07/23/2025?

He purchased 400,000 voting common shares.

What was the purchase price per share in the latest DMAC Form 4?

The shares were bought at $3.50 each.

What is Richard Jacinto II's total ownership after the transaction?

His indirect Roth IRA account now holds 4,958,823 DMAC shares.

Through which account were the DMAC shares acquired?

The acquisition was made via NFS/FMTC Roth IRA FBO Richard Jacinto II.

Were any derivative securities reported in this DMAC Form 4 filing?

No, Table II lists no derivative securities.
Aon Plc

NYSE:AON

AON Rankings

AON Latest News

AON Latest SEC Filings

AON Stock Data

77.15B
209.47M
3.07%
89.19%
2.56%
Insurance Brokers
Insurance Agents, Brokers & Service
Link
Ireland
DUBLIN 2